In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model

Iwan P. Williams, Silvia Crescioli, Heng Sheng Sow, Heather J. Bax, Carl Hobbs, Kristina M. Ilieva, Elise French, Giulia Pellizzari, Vivienne Cox, Debra H. Josephs, James F. Spicer, Sophia N. Karagiannis, and Silvia Mele

ABSTRACT

IgE monoclonal antibodies hold great potential for cancer therapy. Preclinical in vivo systems, particularly those in which the antibody recognizes the host species target antigen and binds to cognate Fc receptors, are often the closest approximation to human exposure and represent a key challenge for evaluating the safety of antibody-based therapies. We sought to develop an immunocompetent rat system to assess the safety of a rodent anti-tumor IgE, as a surrogate for the human therapeutic candidate. We generated a rat IgE against the human tumor-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) and cross-reactive for the rat antigen. We analyzed CSPG4 distribution in normal rat and human tissues and investigated the in vivo safety of the antibody by monitoring clinical signs and molecular biomarkers after systemic administration to immunocompetent rats. Human and rat CSPG4 expression in normal tissues were comparable. Animals receiving antibody exhibited transient mild to moderate adverse events accompanied by mild elevation of serum tryptase, but not of angiotensin II or cytokines implicated in allergic reactions or cytokine storm. In the long term, repeated antibody administration was well tolerated, with no changes in animal body weight, liver and kidney functions or blood cell counts. This model provides preclinical support for the safety profiling of IgE therapeutic antibodies. Due to the comparable antigen tissue distribution in human and rat, this model may also comprise an appropriate tool for proof-of-concept safety evaluations of different treatment approaches targeting CSPG4.

Introduction

Using recombinant monoclonal antibodies (mAb) of the IgE class for immunotherapy of cancer is an innovative approach that has shown promising results in vitro and in vivo.1–3 MAbs for the treatment of cancer are typically designed as IgGs, but use of such molecules has drawbacks, including: 1) relatively low affinity for cognate Fcγ receptors; 2) short half-life in tissues; and 3) the expression of inhibitory Fcγ receptors (FcγRIIB) on immune cells in the tumor microenvironment (TME), which may limit the effector functions and potency of IgGs to promote immune surveillance against solid tumors.4,5 In contrast, IgE displays up to 10,000-fold higher affinities for and slow dissociation from cognate Fcε receptors on IgE effector cells often found in the TME, lacks inhibitory FcεRs, is retained for longer than IgG in tissues, and can exert immune surveillance in Th2-biased environments such as the TME.2,5–8 These attributes of IgE, actively investigated in the field of AllergoOncology, may be harnessed for cancer immunotherapy.1,2,9 Several studies in disparate animal models have demonstrated the anticancer efficacy of IgE mAbs directed to tumor antigens, including immunocompetent human FcεRIα transgenic mice treated with chimeric or humanized IgE antibodies,10–12 syngeneic murine and rat carcinoma models,13–15 and immunocompromised SCID mouse models bearing human carcinoma xenografts.16–18 When compared to their IgG counterparts, IgE mAbs showed superior anti-tumor efficacy,10,16–19 which could be at least partly due to the IgE-mediated reprogramming of monocytes and macrophages within the tumor microenvironment.18,19–22 A first-in-human Phase 1 study (NCT02546921) of MOv18 IgE, a chimeric IgE antibody against folate receptor-alpha (FRα), has been initiated at King’s College London sponsored by Cancer Research UK. However, the pivotal role of IgE antibodies in the allergic response and systemic hypersensitivity reactions represents the main concern in the use of IgE mAbs for passive immunotherapy.

Due to the multimodal activity of therapeutic mAbs, it is challenging to find one animal model that can recapitulate the complexity of the tumor microenvironment, the human...
Conversely, rat Fcα was comparable to that exhibited by the human FcεRI that makes it a more suitable rodent model for the study of IgE-mediated cancer immunotherapy. Previous animal models used to evaluate the ability of a murine anti-CSPG4 antibody (clone 225.28) to cross-react with human CSPG4 and its rat orthologue, we observed CSPG4 expression along blood vessels in rat and human uterus tissues (Figure 1I, J). Human bone marrow, thyroid gland and adenohypophysis showed moderate CSPG4 expression, whereas no expression was detected in human peripheral nerve, cerebellum and esophagus tissues (Supplemental Figure 2, data for the respective rat tissues are not available). Moreover, when comparing CSPG4 gene expression in normal tissues of four different species through interrogation of transcriptomic datasets (EMBL-EBI Expression Atlas), human and rat showed similar expression profiles (Figure 1M).

Generation and functional characterization of α-CSPG4 rIgE

We successfully generated α-CSPG4 rIgE, a rat IgE containing the variable regions of the light and heavy chains derived from the murine anti-CSPG4 clone 225.28 (Supplemental Figure 1). SDS-PAGE analysis of α-CSPG4 rIgE confirmed the predicted molecular size in both non-reducing and reducing conditions (Figure 2A). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and high performance liquid chromatography-size exclusion chromatography (HPLC-SEC) profiles of α-CSPG4 rIgE were comparable to those of the previously-described rat antibody MOv18 rIgE, which recognizes the human FcεRI (Figure 2A, B). Flow cytometric analysis showed that α-CSPG4 rIgE was able to bind the human CSPG4-expressing melanoma cell line A2058 in a dose-dependent manner and similarly to its human counterpart, α-CSPG4 hIgE (Figure 2C), with 50% of the maximal mean fluorescence intensity reached by the two antibodies at similar concentration (1.57 µg/ml α-CSPG4 rIgE and 1.11 µg/ml α-CSPG4 hIgE). Comparable binding of α-CSPG4 rIgE to the rat FcεRI-expressing basophilic RBL-2H3 cells and α-CSPG4 hIgE to the human FcεRI-expressing RBL-SX38 cells was observed (Figure 2D). The binding of the α-CSPG4 rIgE to the rat CSPG4-expressing C6 glial cells was comparable to that exhibited by a commercial polyclonal anti-CSPG4 antibody reactive for rat CSPG4 (Figure 2E) and the α-CSPG4 hIgE. Moreover, in a competition assay, α-CSPG4 rIgE binding to C6 cells was inhibited by the presence of increasing concentrations of the anti-rat CSPG4 antibody, confirming target antigen-binding specificity (Figure 2F). We concluded that the variable region derived from the 225.28 antibody clone was cross-reactive with the rat orthologue of CSPG4.

To further characterize the functional properties of α-CSPG4 rIgE, we tested its ability to activate rat immune effector cells. Crosslinking α-CSPG4 rIgE bound to rat FcεRI-expressing basophilic RBL-2H3 cells led to significant induction of degranulation (Figure 2G), equivalent to that observed using a commercial rat anti-DNP IgE. No degranulation was observed by either antibody in the absence of the crosslinking agent. Moreover, α-CSPG4 rIgE triggered RBL-2H3-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) against A2058 cells (Figure 2H, I). No anti-tumor effect was observed in vivo mouse colony stimulation assays and the multifaceted mechanisms of action of mAbs whilst concurrently allowing a comprehensive analysis of safety. Preclinical models for the study of therapeutic antibody safety should ideally offer: 1) an intact immune system that can mimic the expression and binding of human Fc receptors in the relevant immune cell populations; 2) a relevant tissue distribution of the target antigen; and 3) cross-reactivity of the antibody with orthologues of its respective human target.

Murine models are not considered representative of human IgE biology, primarily because of the substantial inter-species differences in the structure and expression pattern of the high-affinity IgE receptor. Conversely, rat FcεRI shares distinct features with human FcεRI that make it a more suitable rodent model for the study of IgE-mediated cancer immunotherapy. In particular, unlike mouse, both rat and human FcεRI can be expressed either as a trimeric (αβε) or a tetrameric form (αβεγ), and expression is not restricted to basophils and mast cells but it can be found in other immune cells such as eosinophils, dendritic cells and macrophages. Previous animal models used to test IgE passive immunotherapy did not report antibody cross-reactivity between the target human antigen and the orthologue of the host species, with the exception of a pilot study where a single infusion of 0.08 mg/kg anti-HER2/neu IgE was injected into a cynomolgus monkey. The clinical translation of IgE immunotherapy in solid cancers is now moving forward, and further studies are needed to elucidate its safety profile and applicability across different tumor types and target antigens.

Chondroitin-sulfate proteoglycan 4 (CSPG4), also known as neuronal-glial antigen 2 (NG2), is considered a promising candidate target for cancer immunotherapy because of its diffuse and high level expression in a broad range of tumor types, such as melanoma, glioblastoma and subsets of breast carcinomas.

Here, we designed a rat model to study the safety of a monoclonal IgE antibody directed against CSPG4. The distribution of human CSPG4 and its rat orthologue were evaluated in normal human and rat tissues. Taking advantage of the ability of a murine anti-CSPG4 antibody (clone 225.28) to cross-react with human CSPG4 and its rat orthologue, we generated a surrogate rat IgE mAb, α-CSPG4 rIgE, and looked for in vivo immediate and long-term adverse effects in immunocompetent rats through analysis of clinical signs and molecular biomarkers.

Results

CSPG4 distribution in rat and human normal tissues

In order to test the relevance of a rat model in the context of the safety of a CSPG4-targeted antibody, we compared the distribution of CSPG4 across a range of human and rat normal tissues. Similar patterns of CSPG4 expression were observed between the two species (Figure 1A–L). In agreement with studies that have reported the expression of CSPG4 in oligodendrocyte progenitor cells of the central nervous system (CNS), we detected CSPG4-positive cells in rat and human cerebrum (Figure 1A,B). In lung and liver tissues, we observed scattered cells with a moderate expression of CSPG4, whereas low expression was detected in pneumocytes (Figure 1E, F) and hepatocytes (Figure 1G, H). In line with previous studies that identified CSPG4 as a marker of angiogenic vasculature, we observed CSPG4 expression along blood vessels in rat and human uterus tissues (Figure 1I, J). Human bone marrow, thyroid gland and adenohypophysis showed moderate CSPG4 expression, whereas no expression was detected in human peripheral nerve, cerebellum and esophagus tissues (Supplemental Figure 2, data for the respective rat tissues are not available). Moreover, when comparing CSPG4 gene expression in normal tissues of four different species through interrogation of transcriptomic datasets (EMBL-EBI Expression Atlas), human and rat showed similar expression profiles (Figure 1M).
observed in A2058 cells treated with up to 250 µg/ml α-CSPG4 rIgE (Figure 2J). These findings indicated that the Fc region of α-CSPG4 rIgE was structurally functional, with ability to induce immune effector functions.

Immediate reactions to α-CSPG4 rIgE administration

We next investigated the safety profile of α-CSPG4 rIgE in an immunocompetent rat model. Rats were injected via the tail...
Figure 2. In vitro characterization of α-CSPG4 rIgE antibody. A, SDS-PAGE of reduced (DTT+) and non-reduced (DTT-) α-CSPG4 rIgE and MOv18 rlgE. B, HPLC-SEC profile of α-CSPG4 rIgE and MOv18 rlgE. C, Dose-dependent binding of α-CSPG4 rIgE (left) and α-CSPG4 hlgE (right) to CSPG4-expressing human A2058 cells detected by flow cytometry and expressed as % of maximal binding (maximal Mean Fluorescence Intensity). D, Dose-dependent binding of α-CSPG4 hlgE (left) and α-CSPG4 rlgE (right) to FcεRI-expressing RBL-SX38 (left) and RBL-2H3 cells (right) detected by flow cytometry. Representative results of one of four (RBL-SX38) and one (RBL-2H3) independent experiments. E, Binding profiles of commercial polyclonal anti-rat CSPG4 (AB5320), α-CSPG4 rlgE and α-CSPG4 hlgE to CSPG4-expressing rat C6 cells. F, Competition between increasing concentrations of rabbit AB5320 antibody (or MOv18 hlgE as control) and α-CSPG4 rlgE (detected with a secondary anti-rat IgE antibody) binding to C6 cells. G, RBL-2H3 cells degranulation in the absence of stimuli (HBSS), in the presence of α-DNP rlgE or α-CSPG4 rlgE alone, or upon crosslinking with α-lgE secondary antibody. Cells treated with Triton-X100 were set as 100%. Bars indicate mean ± SD from 3 independent experiments. **p < .01 by one-way ANOVA. H and I, RBL-2H3 cells-mediated ADCC against CFSE-labeled A2058 cells pre-coated with α-CSPG4 rlgE or α-DNP rlgE. H, Representative dot plot obtained in the presence of α-DNP rlgE (left panel) or α-CSPG4 rlgE (right panel). The percentage of dead cells was defined as DAPI+ A2058 cells (red box)*100/total A2058 cells (purple box). I, ADCC data obtained from 3 independent experiments. Bars indicate mean ± SD; *p < .05 by one-way ANOVA. J, A2058 cells proliferation after incubation with α-CSPG4 rlgE or α-DNP rlgE (4 days). Incubation with no antibody was set as 100%. Data are the mean of 3 independent replicates.
vein with a single dose of 10 mg/kg α-CSPG4 rlgE, MOv18 rlgE or phosphate-buffered saline (PBS). Clinical signs were monitored for 1 hour after injection and observations summarized based on a previously reported scoring system (Supplementary Table 2). None of the animals treated with PBS presented abnormal or adverse effects, and injection of MOv18 rlgE induced mild reactions in agreement with previous findings (Table 1). Following α-CSPG4 rlgE injection, transient mild or moderate adverse reactions were observed within 5 minutes, namely labored respiration, prostration, piloerection, reduced responsiveness and no peer interactions, but no severe reactions were observed. Symptoms resolved within 30 minutes from injections. Within the α-CSPG4 rlgE-treated group, we did not observe differences in the reactions of animals whether they were previously injected with untransfected CC531 or transfected CC531-hCSPG4 cells (Table 1, Supplemental Figure 3), indicating that the reactions observed were not due to the antibody encountering ectopically-expressed human CSPG4. A notable symptom observed in the α-CSPG4 rlgE-treated animals was that they started drinking earlier ~20 to 30 minutes after injection.

To gain insight into the molecular mechanisms linked with the adverse symptoms observed, we analyzed hypersensitivity biomarkers 30 minutes after antibody injection. Animals injected with MOv18 rlgE and PBS showed similar serum levels of the serine esterase tryptase (PBS: 4.6 ng/ml ± 1.2; MOv18 rlgE: 5.1 ng/ml ± 0.3, p = .97), whereas we observed higher levels of serum tryptase in animals treated with α-CSPG4 rlgE (8.3 ng/ml ± 1.2, p = .035) (Figure 3A). Levels of serum angiotensin II, a vasoconstrictor thought to be endogenously released following anaphylactic reaction to counteract the vasodilation, did not differ between treatments 30 minutes after injection (PBS: 67.4 pg/ml ± 18.4; MOv18 rlgE: 66.3 pg/ml ± 9.9; α-CSPG4 rlgE: 64.3 pg/ml ± 17.3) (Figure 3B). No significant differences were observed in serum levels of interleukin (IL)-10 and tumor necrosis factor (TNF) of α-CSPG4 rlgE-treated animals when compared to PBS (Figure 3C). Similarly, the levels of RANTES did not differ between the different groups. However, the serum levels of eotaxin, IL-2, IL-4, IL-12p70, IL-1α, IL-5, IL-6 and IL-13 decreased in the sera of animals treated with α-CSPG4 rlgE compared to PBS (Figure 3C). In particular, the Th2 type cytokines IL-6, IL-13, IL-4 and IL-1α showed ~70% decrease. Consistent with previous reports, we observed a partial increase in the levels of IL-10 and TNF following treatment with MOv18 rlgE (Figure 3C).

Long-term safety profile of α-CSPG4 rlgE

We next sought to investigate the effects of repeated exposure to α-CSPG4 rlgE by injecting 5 mg/kg of α-CSPG4 rlgE on days 1, 2, 4, 7 and 14. Urine samples were collected immediately before, 3 hours and 24 hours after the last α-CSPG4 rlgE administration (Figure 4A).

After α-CSPG4 rlgE injection on day 14, the animals showed immediate adverse reactions as described above accompanied by the release of histamine, which was detected in the urine of α-CSPG4 rlgE-treated animals (4.31 ± 2.77 ng/ml) and dropped below the limit of detection (0.098 ng/ml) after 24 hours (Figure 4B). Repeated α-CSPG4 rlgE administrations did not affect animal body weight, which was comparable between treatments (Figure 4C). No differences in the urine levels of kidney function markers, namely β-2-microglobulin, calbindin, clusterin, interferon-inducible protein 10 (IP-10), osteopontin, kidney injury molecule-1, cystatin C, TIMP-1 or vascular endothelial growth factor were detectable between treatment groups before and 24 hours after the last injection (Figure 4D), indicating normal function. Notably, urine levels of lipocalin-2 (LCN2) were increased 24 hours after α-CSPG4 rlgE administration (Figure 4D).

At experimental day 28, animals were sacrificed, and blood samples were collected (Figure 5A). We did not observe changes in the serum levels of the liver damage-associated markers creatinine, alanine transaminase, 5'-nucleotidase or glutamic-oxaloacetic transaminase (Figure 5B). Similarly, blood hemoglobin concentration and blood cell counts (Figure 5C, D) were comparable between groups. Levels of serum cytokines, found altered immediately after α-CSPG4 rlgE treatment, did not differ between treatment groups at day 28 (Figure 5E). These data indicate that repeated α-CSPG4 rlgE administrations did not induce signs of long-term toxicity.

| Table 1. Clinical signs observed following α-CSPG4 rlgE, MOv18 rlgE or PBS administration. |
|---------------------------------------------------------------|
| **Drinking**                  | **PBS** (n = 4) | **MOv18 rlgE** (n = 4) | **α-CSPG4 rlgE** (n = 4) | **α-CSPG4 rlgE** (n = 3) |
|--------------------------------|----------------|----------------------|------------------------|------------------------|
| **Piloerection**                | Normal         | Normal               | Abnormal behaviour     | Abnormal behaviour     |
| **Responsiveness**              | Normal         | Mild                 | Moderate               | Moderate               |
| **Peer interaction**            | Normal         | Normal-Mild          | Moderate               | Moderate               |
| **Hunching**                    | Normal         | Normal               | Mild                   | Mild                   |
| **Vocalisation**                | Normal         | Normal               | Normal                 | Normal                 |
| **Oculo-nasal discharge**       | Normal         | Normal               | Normal                 | Normal                 |
| **Respiration**                 | Normal         | Normal               | Moderate               | Moderate               |
| **Tremors**                     | Normal         | Normal               | Normal                 | Normal                 |
| **Convulsions**                 | Normal         | Normal               | Normal                 | Normal                 |
| **Prostration**                 | Normal         | Normal               | Moderate               | Moderate               |
| **Self-mutilation**             | Normal         | Normal               | Normal                 | Normal                 |

aCC531-hCSPG4 cells injected via tail vein 24 hours before antibody administration.
bCC531 cells injected via tail vein 24 hours before antibody administration.
Discussion

The ongoing Phase 1 clinical study (NCT02546921, [www.clinicaltrials.gov](http://www.clinicaltrials.gov)) of MOv18, a first-in-class therapeutic IgE antibody for ovarian cancer therapy, represents a substantial advance for the field, and it underlines the importance of further exploration of the safety profile and clinical applicability of IgE therapeutics against different tumor targets.

Here, we investigated the in vivo safety of a surrogate antibody of the IgE class in immunocompetent rats, chosen because of the similarities in the structure and immune distribution of human and rat FcεRI, as previously described.\textsuperscript{15,24} Moreover, the antibody tested here recognizes the rat orthologue of its human target, CSPG4, making this model particularly relevant, as antigen cross-reactivity has not until now been reported in the context of IgE-based treatments.

CSPG4 is a promising target antigen highly expressed in multiple tumor types, including melanoma, glioblastoma, breast carcinomas, osteosarcoma and hematologic cancers.\textsuperscript{25,35} Originally believed to have a very limited distribution in normal adult tissues,\textsuperscript{36} CSPG4 expression has since been observed...
in a wider range of organs, but preferentially associated with progenitor cell phenotypes. Accordingly, we detected low to moderate expression of CSPG4 in some human anatomical locations including the CNS, spleen, bone marrow and endocrine organs like the thyroid gland and adenohypophysis. The distribution of the rat orthologue of CSPG4 in normal rat tissues was comparable to that observed in humans, as detected by screening different anatomical locations using tissue microarrays.

At present, despite the large amount of preclinical data on the anti-tumor efficacy of CSPG4-targeting therapies, few clinical studies have been reported. Early-phase clinical trials conducted in patients with malignant melanoma showed that immunization with the CSPG4 mouse anti-idiotypic antibody MK2-23 induced the production of anti-CSPG4 antibodies and correlated with survival prolongation without reporting target-related toxicity. Similarly, intravenous injection of the $^{213}$Bi-cDTPA-9.2.27 immunotherapeutic agent, based on the mouse anti-CSPG4 9.2.27 mAb and the $^{213}$Bi α-particle-emitting radioisotope, did not cause adverse events when administered to metastatic melanoma patients up to a dose of 925 MBq in a Phase 1 clinical trial. In light of the possibility of on-target/off-tumor toxicities due to the expression of CSPG4 in normal tissues, and based on known toxicity effects of systemically-administered CAR-T cell therapies, intracranial (intratumor) delivery was adopted instead of intravenous administration in a recent study on CAR-T cells based on the anti-CSPG4 mAb clone 763.74 in a xenograft murine model of glioblastoma.

Here, we attempted to recreate a model for the study of on-target/off-tumor toxicity effects, which raise particular concern in systemically administered therapeutic agents. Using stable transfection, we produced a functionally-active surrogate rat IgE antibody, α-CSPG4 rIgE, based on the constant regions of rat IgE and the variable regions of the anti-CSPG4 rIgE.
murine antibody 225.28.\textsuperscript{42,43} The α-CSPG4 rIgE was able to induce mast cell degranulation upon crosslinking and to mediate tumor cell killing upon binding to rat FcεRI-expressing effector cells, attributes previously shown with other IgE antibodies targeting cancer antigens.\textsuperscript{10,44,45}

Intravenous injection of 5–10 mg/kg α-CSPG4 rIgE into Wistar Albino Glaxo (WAG) rats, with dosage selected based on previous studies of safety and anti-tumor efficacy of MOv18 IgE in a similar rat model,\textsuperscript{15} induced temporary mild to moderate adverse effects, such as labored respiration, prostration, piloerection and reduced responsiveness, which resolved within 30 minutes of injection. The reactions were observed in α-CSPG4 rIgE-treated animals regardless of the ectopic expression of the human target in previously-inoculated cell line CC531. As we demonstrated that α-CSPG4 rIgE recognizes the rat orthologue of CSPG4, we hypothesized that the interaction of the antibody with the rat tissues could be responsible for the transient reactions observed. Moreover, our control antibody MOv18 rIgE, which is thought not to recognize the rat homologue of its human target antigen FRα, did not show the same pattern of clinical signs. On a molecular level, we detected slightly higher levels of serum tryptase\textsuperscript{46} in α-CSPG4 rIgE-treated animals compared with PBS and MOv18 rIgE controls 30 minutes after the treatment and the presence of histamine in the urine 3 hours after antibody injection, which then dropped below the detection limit after 24 hours. These may indicate a temporary IgE-mediated activation of basophils and/or mast cells that self-resolved completely. This process
was not accompanied by any increases in the levels of serum angiotensin II or cytokines, such as TNF, IL-2, IL-4, IL-5, IL-6, IL-10 and IL-13 among others, normally reported as a concomitant event during anaphylactic reactions. Conversely, most of the cytokines tested here were significantly downregulated 30 minutes after the injection of α-CSPG4 rIgE. This was the case for IL-2, IL-4, IL-5, IL-6, IL-13, IL-1α, IL-12 (p70) and eotaxin (CCL-11). As blood withdrawal was performed after sacrificing the animals, our serum cytokine analysis was limited by the lack of multiple time-points. Further studies will be needed to dissect the molecular interplay and the dynamics of the immune mediators involved. Interestingly, we found significantly elevated LCN2 levels in the urine of α-CSPG4 rIgE-treated rats 24 hours after antibody administration. Besides its role as a biomarker of acute kidney injury, LCN2 was identified as mediator of the innate immune response and a protective component during the development of airway hyperreactivity and inflammation in a murine model of allergic airway. Moreover, elevated serum levels of LCN2 were found to be associated with improvement in the quality of life of patients with chronic urticaria. In light of these studies, our data may indicate a specific role for LCN2 in the IgE-mediate immune response, possibly by acting as a negative feedback in the inflammatory cascade.

Long-term, repeated antibody treatment did not affect the general health of the animals; their weight, blood cell counts, and metabolic markers of kidney and liver functions were comparable to the control group. Similarly, when tested 7 to 14 days after antibody injection, the levels of the cytokine and biomarkers in serum and urine were not different compared to controls.

In summary, our study provides the safety profile of passive IgE immunotherapy in a rodent species that features comparable expression of the target antigen and antibody cross-reactivity between the target human antigen and the orthologue of the host species. As administration of high doses (5–10 mg/kg) of α-CSPG4 rIgE induced only temporary mild to moderate adverse effects, our findings support the rationale for evaluating IgE-based compounds as immunotherapeutic agents. As the pharmacological translation from rodent to human is limited by the lack of knowledge on several aspects of rodent immunology, further insights into the safety of IgE-based immunotherapy will be provided by future studies on primates and reports from the current clinical study. Here, the comparable distribution of CSPG4 in human and rat normal tissues renders this system a useful platform for proof-of-concept studies on the safety and toxicology of different biological and immune therapies targeting CSPG4, including those based on the 225.28 clone, the efficacy of which has been extensively described against different solid tumors and in several formulations. By remodeling the tumor microenvironment and harnessing anti-tumor surveillance by immune effector cells such as macrophages, IgE antibodies may overcome tumor-induced immunomodulating forces that restrict the effectiveness of IgGs in tumor-targeted antibody therapy. On the other hand, the faster clearance of IgEs compared to IgGs could represent a challenge in terms of tumor penetration and pharmacokinetic properties and should be further investigated. Whether the higher affinity of IgE to its Fcε receptors compared to that of IgGs for cognate Fcγ receptors can compensate for a lower concentration of antibody at the tumor site still need to be determined. Future studies focused on IgE biodistribution will help to a better understand the potential of this class and its applicability in different therapeutic indications.

**Materials and methods**

**Cell culture**

The human Expi293F cell line (ThermoFisher Scientific) was grown in Expi293F expression medium (Gibco) under shaking condition (125 rpm) at 8% CO₂ in a 37°C humidified incubator. All other cell lines used were maintained in 37°C humidified 5% CO₂ incubator. Human melanoma cell line A2058 and rat glial C6 cells (ATCC) were grown in DMEM (Gibco) supplemented with 10% and 15% fetal bovine serum (FBS) (Gibco) respectively. Rat FceRI-expressing basophilic RBL-2H3 cells (ATCC) were grown in MEM (Gibco) containing 15% FBS. Human FcεRI-expressing basophilic rat RBL-SX38 cells (ATCC) were grown in RPMI1640 (Gibco) medium containing 10% FBS. The WAG rat-derived colon adenocarcinoma cell line CC531 cells (CLS Cell Lines Service GmbH) were grown in RPMI1640 (Gibco) containing 10% FBS.

CC531 was transfected with a pDEST26 vector encoding for the full-length human CSPG4 (Source Bioscience) using Lipofectamine 2000 according to manufacturer’s instructions. Cells were maintained under selection with 200 μg/ml G418 antibiotic (GE Healthcare) for 4 weeks, then stained with allophycocyanin (APC)-conjugated anti-CSPG4 (clone: REA1041, Miltenyi Biotec) and APC+ cells were analysed using a BD FACSAria cell sorter (BD Biosciences). The WAG rat-derived colon adenocarcinoma cell line CC531 was transfected with a pDEST26 vector encoding for the full-length human CSPG4 (Source Bioscience) using Lipofectamine 2000 according to manufacturer’s instructions. Cells were maintained under selection with 200 μg/ml G418 antibiotic (GE Healthcare) for 4 weeks, then stained with APC-conjugated anti-CSPG4 (clone: REA1041, Miltenyi Biotec) and APC+ cells were analysed using a BD FACSAria cell sorter (BD Biosciences).

**Immunohistochemistry analysis of CSPG4 expression**

The multiple organ normal tissue microarray FDA999g was purchased from US Biomax. Tissues were de-waxed with Xylene, followed by rehydration with ethanol. Heat-induced antigen retrieval was performed in a 95°C water bath, using citric acid. Subsequently, sections were stained following standard immunohistochemistry (IHC) procedures using the commercial mouse monoclonal anti-CSPG4 antibody (clone: LHM-2, Abcam). IHC detection of orthologue rat CSPG4 on the paraffin-embedded rat normal tissue array (RAT901A)
was performed by US Biomax using the commercial rabbit polyclonal anti-NG2 antibody (AB129051, Abcam).

**Gene expression analysis**

CSPG4 gene expression data in different species were obtained from the databases indicated through interrogation of EBI search. When more than one dataset was available, data were presented as mean ± SD using GraphPad Prism.

**Cloning and production of recombinant antibodies**

For generation of an anti-CSPG4 rat/mouse chimeric IgE (α-CSPG4 rlgE), codon-optimized gBlock gene fragments (Integrated DNA Technologies), one encoding for the anti-CSPG4 antibody (clone 225.28) heavy chain variable region fused to the rat epsilon heavy chain constant domains, and the other encoding for 225.28 light chain variable region fused to the mouse kappa light chain constant domains, were cloned into two separate UCOE Mu-H plasmids (Merck Millipore) using polymerase incomplete primer extension as previously described (Supplemental Figure 1; Supplemental Table 1). 31,42,58

Expi293F cells were co-transfected with the two vectors using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Culture supernatant was tested for α-CSPG4 rlgE secretion via A2058 cells staining as described in the Supplemental Methods. For antibody production, cells were seeded at 2x10⁶/ml and cultured for 24h. The antibody was purified from supernatant with HiTrap Protein L affinity columns (GE Healthcare) and dialyzed against PBS using Tube-O-DIALYZER (G-Biosciences). The anti-CSPG4 human/mouse chimeric IgE antibody (α-CSPG4 hlgE), also based on the mouse antibody clone 225.28, and the anti-FRα rat MOv18 IgE (MOv18 rlgE) were produced as described. 15,31

**Analysis of antibody purity**

Antibody purity was verified by SDS-PAGE and SEC. For SDS-PAGE, purified antibodies (5µg) were mixed with Laemmli sample buffer (Bio-Rad Laboratories) and heated at 95°C for 5min. Samples and protein ladder (PageRuler Plus 10–250kDa, ThermoFisher Scientific) were then run on a 4–15% Mini-PROTEAN TGX gel (Bio-Rad Laboratories) and stained with Cooomassie dye (Expeideon). For SEC, antibodies were analyzed using a Superdex 200 10/300 GL column (GE Healthcare) using a Gilson HPLC system.

**Flow cytometry**

To test in-house produced antibody binding to CSPG4, cells were detached using 5 mM ethylenediaminetetraacetic acid (EDTA) in PBS, resuspended at 1 × 10⁶ cells/ml and incubated on ice for 30 min with the indicated concentration (10 µg/ml, if not specified) of primary antibodies in fluorescence-activated cell sorting (FACS) buffer (2% FBS in PBS). Cells were then washed and incubated with fluorescently-labeled secondary antibody in FACS buffer for further 30 min, washed twice and analyzed using a BD FACS Canto II flow cytometer (BD Biosciences). For competition binding assay, C6 cells were incubated with increasing concentrations of unlabeled competitor rabbit polyclonal anti-CSPG4 antibody (AB5320, Abcam) or MOv18 hlgE as isotype control together with 5 µg/ml of the in-house produced rat anti-CSPG antibody, which was detected with a fluorescein isothiocyanate (FITC)- conjugated anti-rat IgE (MA516812, Invitrogen). The commercial APC-conjugated anti-human CSPG4 (clone: REA1041, Miltenyi Biotec) was used as a positive control to detect CSPG4 in human cell lines. The FITC-conjugated anti-human IgE (FI-3040, Vector Laboratories) was used as a secondary antibody to detect in-house produced human IgEs.

**Cell proliferation assay**

A2058 cells were seeded in 96-well plates (1x10³/well) and incubated with varying concentrations of antibody or PBS in growing media to a final volume of 100 µl. After 4 days, media was replaced with 100 µl of fresh media containing CellTitertm AQueousOne Solution Reagent (G3582, Promega) according to manufacturer instructions. Cells were then incubated for 2 hours at 37°C in the dark in a humidified 5% CO₂ incubator. Absorbance at 490 nm and background at 690 nm was read using a FluoStar Omega microplate reader (BMG Labtech). The relative cell proliferation (%) was calculated as the absorbance of antibody-treated cells/absorbance of PBS-treated cells.

**Bead-based multiplex and ELISA assays**

Levels of selected cytokines in the rat serum were measured by bead-based Multiplex assay kit (RECYTMAG-65K, Millipore) according to the manufacturer’s instructions using a FlexMap 3D (Luminex). Serum levels of angiotensin II and tryptase were measured via ELISA kits (CSB-E04494r, CSB-E13627r, Cusabio Technology). Biomarkers of kidney-related toxicity were measured in the rat urine by bead-based Multiplex assay kit (RTX1MAG-37K and RTX2MAG-37K, Millipore) according to the manufacturer’s instructions. ELISA kit (ab213975, Abcam) was used to determine histamine levels in the rat urine.

**Antibody-induced cell degranulation**

The IgE-mediated RBL-2H3 cell degranulation assay was performed according to a previously described method 39 with modifications. RBL-2H3 cells (1x10³/well) were incubated with 1 µg/ml of in-house produced α-CSPG4 rlgE, a commercial rat monoclonal anti-DNP IgE (MAS-16776, Invitrogen) or left untreated for 1hr at 37°C. Cells were then washed with HBSS (Gibco) and incubated with either HBSS, 0.1% Triton-X100 in HBSS or 1 µg/ml of polyclonal goat anti-rat IgE (PA1-29379, ThermoFisher Scientific) as crosslinker for 2 hr. An aliquot of supernatant (50 µl) was then diluted 1:1 in HBSS and incubated with 50 µl of fluorescent substrate (final concentration: 0.5 mM 4-methylumbelliferyl N-acetyl-β-D-glucosaminide, 0.05% DMSO, 0.05% TritonX-100, 100 mM citrate buffer pH4.5) for 2 hr at 37°C in a Nunc-ImmuNo° black 96-well plate. The reaction was quenched
with 1:1 0.5 M Tris-HCl pH 8.2 and fluorescence detected using a Fluostar Omega microplate reader (BMG Labtech) with excitation and emission wavelengths of 350 nm and 450 nm.

**Antibody-dependent cell-mediated cytotoxicity**

A2058 cells (target) were stained in PBS containing 5 μM CellTrace™ CFSE (ThermoFisher Scientific). After 24 h, cells were detached with 5 mM EDTA in PBS and incubated with the desired antibody (10 μg/million cells) or an equivalent volume of PBS at 37°C for 30min. A2058 cells were then washed, resuspended at 5x10⁷/ml in 100 μl of MEM containing 2% FBS and mixed with previously trypsinized RBL-2H3 cells (effector) at 1:1 effector:target ratio. After 2 h incubation at 37°C in 5% CO₂, DAPI (ThermoFisher Scientific) was added to the samples and the fluorescence was acquired using a BD FACSCanto II flow cytometer (BD Biosciences). Cells were gated based on forward and side scatter, and quadrant gates were applied to determine the % DAPI+ A2058 cells (DAPI+ CFSE⁺ *100/total CFSE⁺*).

**Immunocompetent WAG rat model**

Female WAG/RijCrl rats 6–8 weeks old were purchased from Charles River. All procedures were performed in accordance with the Institutional Committees on Animal Welfare of the UK Home Office and under The Home Office Animals Scientific Procedures Act, 1986. Antibodies at the specified concentration or an equivalent volume of PBS were injected via the tail vein at the indicated time points. Where indicated, CC531 cells and CC531-hCSPG4 transfected cells (3–4 x 10⁶) were injected via the tail vein. Animals were monitored and symptoms were scored using scoring criteria reported in Supplemental Table 1. At the end of the experiments, animals were culled by asphyxiation with carbon dioxide and blood samples were collected. For serum isolation, blood samples in Microvette® tubes (Sarstedt) were spun at 10,000 g for 10 min and separated serum was stored at −80°C. Blood collected into EDTA-containing tubes was used for cell counts. Measurement of serum hemoglobin, creatinine, alanine aminotransferase and blood cell counts were performed by Sequani Ltd. Urine was collected at the times indicated and stored at −80°C.

**Statistical analysis**

Data are presented as mean ± SD. For statistical comparison of one independent variable, one-way ANOVA with Tukey’s multiple comparisons test was calculated. For grouped data, two-way ANOVA was calculated and Sidak’s multiple comparisons test was applied. P values <.05 were considered statistically significant. Statistical analysis was performed using GraphPad Prism software (version 7.03).

**Acknowledgments**

We thank Ms. Harriet Gilbert-Jones and Dr Sara Lombardi for assistance. We acknowledge the Biomedical Research Centre (BRC) Immune Monitoring Core Facility team at Guy’s and St Thomas’ NHS Foundation Trust for flow cytometry facilities and assistance and the Cancer Research UK King’s Health Partners Centre at King’s College London.

**Disclosure of interest**

Vivienne Cox, Sophia N. Karagiannis and James F. Spicer are founders and shareholders of IGEM Therapeutics Ltd. Heng Sheng Sow and Heather J. Bax are funded through a grant by IGEM Therapeutics Ltd. Sophia N. Karagiannis holds a patent on anti-tumor IgE antibodies. All other authors report no conflict of interest.

**Funding**

The authors acknowledge support by the Medical Research Council [MR/L023091/1]; Breast Cancer Now (147), working in partnership with Walk the Walk; Cancer Research UK [C30122/A11527; C30122/A11574]; the Academy of Medical Sciences; the Inman Charity; CR UK/NIHR in England/DoH for Scotland; Wales and Northern Ireland Experimental Cancer Medicine Centre [C10355/A15857]; the Cancer Research UK King’s Health Partners Centre at King’s College London. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London [IS-BRC-1215-20006]. The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article and its Supplementary Material file.

**ORCID**

Iwan P. Williams http://orcid.org/0000-0002-3471-4664
Heng Sheng Sow http://orcid.org/0000-0003-4143-7543
Sophia N. Karagiannis http://orcid.org/0000-0002-4100-7810
Silvia Mele http://orcid.org/0000-0003-3709-5739

**References**

1. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: a novel concept with promise for the treatment of cancer. MAbs. 2014;6:54–72. doi:10.4161/mabs.27029.
2. Sutton BJ, Davies AM, Bax HJ, Karagiannis SN. IgE antibodies: from structure to function and clinical translation. Antibodies (Basel). 2019;8(1):19.
3. Leoh LS, Daniels-Wells TR, Penichet ML. IgE immunotherapy against cancer. Curr Top Microbiol Immunol. 2015;388:109–49. doi:10.1007/978-3-319-13725-4_6.
4. Burgess M, Mapp S, Mazzieri R, Cheung C, Chambers L, Mattarollo SR, Molle P, Gill D, Saunders NA. Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukemia patients. Oncogene. 2017;36:2366–76. doi:10.1038/onc.2016.387.
5. Tada T, Okumura K, Plateau B, Beckers A, Bazin H. Half-lives of two types of rat homocytotropic antibodies in circulation and in the skin. Int Arch Allergy Appl Immunol. 1972;48:116–31. doi:10.1159/000231297.
6. Lawrence MG, Woolfolk JA, Schuyler Al, Stillman LC, Chapman MD, Platts-Mills TA. Half-life of IgE in serum and skin: consequences for anti-IgE therapy in patients with allergic disease. J Allergy Clin Immunol. 2017;139:422–8 e4. doi:10.1016/j.jaci.2016.04.056.
22. Karagiannis SN, Josephs DH, Bax HJ, Spicer JF. Therapeutic IgE antibodies: harnessing a macrophage-mediated immune surveillance mechanism against cancer. Cancer Res. 2017;77:2779–83. doi:10.1158/0008-5472.CAN-17-0428.

23. Daniels TR, Martinez-Maza O, Penichet ML. Animal models for IgE-mediated cancer immunotherapy. Cancer Immunol Immunother. 2012;61:1355–66. doi:10.1007/s00262-011-1169-1.

24. Dombrowicz D, Chibotariu D, Papin JP, Capron A, Capron M. Expression of a functional Fc epsilon RI on rat eosinophils and macrophages. J Immunol. 2000;165:1266–71. doi:10.4049/jimmunol.165.3.1266.

25. Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Sri C, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, et al. Chondroitin sulfate proteoglycan 4 and its potential as an anti-body immunotherapy target across different tumor types. Front Immunol. 2017;8:1911. doi:10.3389/fimmu.2017.01911.

26. Stallcup WB, Beasley L. Biopotential glial precursor cells of the optic nerve express the NG2 proteoglycan. J Neurosci. 1987;7:2737–44. doi:10.1523/NEUROSCI.07-09-2737.1987.

27. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20:6404–12. doi:10.1523/JNEUROSCI.20-17-06404.2000.

28. Murfee WL, Skalak TC, Peirce SM. Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. Microcirculation. 2005;12:151–60. doi:10.1080/107380690904955.

29. Stark K, Eckart A, Haider S, Tircerici A, Lorenz M, von Bruhl ML, Gartner F, Khandoga AG, Legate KR, Pless R, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol. 2013;14:41–51. doi:10.1038/ni.2477.

30. Wang J, Svendsen A, Knieck J, Immervoll H, Skaffesmo KO, Planaguma J, Reed RK, Bjerkvig R, Miletic H, Enger PO, et al. Targeting the NG2/CSPG4 proteoglycan retards tumor growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One. 2011;6:e23062. doi:10.1371/journal.pone.0023062.

31. Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR, Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, et al. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. J Allergy Clin Immunol. 2018;141:1519–23 e9. doi:10.1016/j.jaci.2017.12.986.

32. Leoni G, Rattray M, Fulton D, Rivera A, Butt AM. Immunoaobilization of cells expressing the NG2 chondroitin sulphate proteoglycan. J Anat. 2014;224:216–27. doi:10.1111/joa.12141.

33. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140:335–48. doi:10.1016/j.jaci.2017.06.003.

34. Dittrich AM, Krokowski M, Meyer HA, Quarcio D, Avagyan A, Ahrens B, Kube SM, Witenrath M, Loddenkemper C, Cowland JB, et al. Lipocalin2 protects against airway inflammation and hyperresponsiveness in a murine model of allergic airway disease. Clin Exp Allergy. 2010;40:1689–700. doi:10.1111/j.1365-2222.2010.03480.x.

35. Riccardo F, Tarone L, Iussich S, Giacobino D, Arigoni M, Sammartano F, Morello E, Martano M, Gattino F, Maria RD, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, et al. Chondroitin sulfate proteoglycan 4 and its potential as an anti-body immunotherapy target across different tumor types. Front Immunol. 2017;8:1911. doi:10.3389/fimmu.2017.01911.

36. Stallcup WB, Beasley L. Biopotential glial precursor cells of the optic nerve express the NG2 proteoglycan. J Neurosci. 1987;7:2737–44. doi:10.1523/NEUROSCI.07-09-2737.1987.

37. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20:6404–12. doi:10.1523/JNEUROSCI.20-17-06404.2000.

38. Murfee WL, Skalak TC, Peirce SM. Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. Microcirculation. 2005;12:151–60. doi:10.1080/107380690904955.

39. Stark K, Eckart A, Haider S, Tircerici A, Lorenz M, von Bruhl ML, Gartner F, Khandoga AG, Legate KR, Pless R, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol. 2013;14:41–51. doi:10.1038/ni.2477.

40. Wang J, Svendsen A, Knieck J, Immervoll H, Skaffesmo KO, Planaguma J, Reed RK, Bjerkvig R, Miletic H, Enger PO, et al. Targeting the NG2/CSPG4 proteoglycan retards tumor growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One. 2011;6:e23062. doi:10.1371/journal.pone.0023062.

41. Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR, Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, et al. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. J Allergy Clin Immunol. 2018;141:1519–23 e9. doi:10.1016/j.jaci.2017.12.986.

42. Leoni G, Rattray M, Fulton D, Rivera A, Butt AM. Immunoaobilization of cells expressing the NG2 chondroitin sulphate proteoglycan. J Anat. 2014;224:216–27. doi:10.1111/joa.12141.

43. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140:335–48. doi:10.1016/j.jaci.2017.06.003.

44. Dittrich AM, Krokowski M, Meyer HA, Quarcio D, Avagyan A, Ahrens B, Kube SM, Witenrath M, Loddenkemper C, Cowland JB, et al. Lipocalin2 protects against airway inflammation and hyperresponsiveness in a murine model of allergic airway disease. Clin Exp Allergy. 2010;40:1689–700. doi:10.1111/j.1365-2222.2010.03480.x.

45. Riccardo F, Tarone L, Iussich S, Giacobino D, Arigoni M, Sammartano F, Morello E, Martano M, Gattino F, Maria RD, et al. Identification of CSPG4 as a promising target for translatable combinatorial approaches in osteosarcoma. Ther Adv Med Oncol. 2019;11:1758835919855491. doi:10.1177/1758835919855491.

46. Natali P, Bigotti A, Cavalleri R, Wakabayaski S, Taniguchi M, Ferrone S. Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. J Invest Dermatol. 1985;85:340–46. doi:10.1111/1523-1747.ep1276944.

47. Nicolosi PA, Dollatsasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics. 2015;5:530–44. doi:10.7150/thno.10824.

48. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res. 1995;1:705–13.
39. Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchettefei F, Aaostolids C, Morgenstern A. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy. 2011;3:1041–50. doi:10.2217/ imt.11.97.

40. Pellegrato S, Savolodo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo F, Ferrone S, DiMeco F, et al. Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neuroepithelial: implications for CAR-T cell therapy. Science translational medicine. 2018;10:eaa2731. doi:10.1126/scitranslmed.aao2731.

41. Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79–101. doi:10.1016/j.addr.2017.05.011.

42. Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, Bax HJ, Beavil R, Pang MO, Gould HJ, et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep. 2014;4:5885. doi:10.1038/srep05885.

43. Neri D, Natali P, Petruhl H, Soldani P, Nicotra MR, Vola R, Soldani P, Nicotra MR, Neri P, Mariani M, et al. Recombinant anti-human melanoma antibodies are versatile molecules. J Invest Dermatol. 1996;107:164–70. doi:10.1111/j.1523-1747.ep12329566.

44. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol. 2008;153:401–09. doi:10.1111/j.1365-2222.2008.03553.x.

45. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother. 2009;58:915–30. doi:10.1007/s00262-008-0607-1.

46. Beck SC, Wilding T, Buka RJ, Baretto RL, Huissoon AP, Krishna MT. Biomarkers in human anaphylaxis: a critical appraisal of current evidence and perspectives. Front Immunol. 2019;10:494. doi:10.3389/fimmu.2019.00494.

47. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132:1141–9 e5. doi:10.1016/j.jaci.2013.06.015.

48. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG. Emergency department anaphylaxis I. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol. 2009;124:786–92 e4. doi:10.1016/j.jaci.2009.07.055.

49. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4:265–80. doi:10.2217/bmm.10.12.

50. Flo TH, Smith KD, Sato S, Rodrigez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917–21. doi:10.1038/nature03104.

51. Trinh HK, Pham DL, Ban GY, Lee HY, Park HS, Ye YM. Altered a. Int Arch Allergy Immunol. 2016;171:102–10. doi:10.1159/000452626.

52. Ghose T, Ferrone S, Blair AH, Kralovec Y, Tempsoni M, Singh M, Mammen M. Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunol Immunother. 1991;34:90–96. doi:10.1007/BF01741431.

53. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, et al. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer. 2014;2:25. doi:10.1186/2051-1426-2-25.

54. Kasten BB, PG, Kim H, Fan JD, Ferrone S, Zinn K, Buchbaum D. 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 2018;19(4):925. doi:10.3390/ijms19040925.

55. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010;70:3027–33. doi:10.1158/0008-5472.CAN-09-2824.

56. Singer J, Achatz-Straussberger G, Bentley-Lukschal A, Fazekas-Singer J, Achatz G, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: high innate IgE levels are decisive for the survival of cancer-bearing mice. World Allergy Organ J. 2019;12:100044. doi:10.1016/j.waojou.2019.100044.

57. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan NS, Basutkar P, Tivey ARN, Potter SC, Finn RD, et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 2019;47(W636–W41. doi:10.1093/nar/gkz268.

58. Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraza C, Josephs DH, Spicer JF, et al. AllergoOncology: expression platform development and functional profiling of an anti-HER2 IgE antibody. Allergy. 2019;74:1985–89. doi:10.1111/all.13818. doi:10.1111/all.v74.10.

59. Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy. 2011;41:1400–13. doi:10.1111/j.1365-2222.2011.03770.x.